Eli Lilly reports stronger-than-expected outcomes from its experimental combination therapy EloraTZP, potentially expanding its dominance in cardiometabolic medicine and accelerating its path to late-stage trials.
Eli Lilly said on Tuesday that a mid-stage trial of its experimental obesity and diabetes treatment EloraTZP produced stronger results than either of its individual ingredients alone, a finding that could broaden the company’s lead in cardiometabolic medicine. In a statement released on September 30, 2026, the Indianapolis-based drugmaker said the combination of eloralintide and tirzepatide delivered substantial reductions in both body weight and blood sugar in adults with obesity and type 2 diabetes.
According to Lilly’s phase 2b study, patients taking the highest-dose combination lost an average of 54.1 pounds, or 23.3% of their body weight, over 48 weeks, while average A1C fell by 2.9 percentage points. That compared with 34.4 pounds, or 14.8%, and a 2.4-point A1C reduction for tirzepatide alone at 15 milligrams. Eloralintide by itself also produced meaningful benefit in earlier testing, with the company reporting last year that the amylin receptor agonist led to weight loss of up to 20.1% in a separate phase 2 study of people with obesity or overweight.
The latest results add to a growing body of evidence behind Lilly’s weight-loss franchise, which already includes Mounjaro and Zepbound, both based on tirzepatide. Reuters reported that the company now plans to begin phase 3 trials of EloraTZP in the fourth quarter of 2026, a key step that would move the programme closer to possible regulatory submission if later studies confirm the early signal. The trial also matters because it suggests Lilly may be able to build on tirzepatide’s already strong performance by combining it with a second mechanism aimed at appetite and metabolic control.
Investor attention to the stock has remained intense as Lilly expands beyond diabetes into obesity, neuroscience, oncology and immunology. GuruFocus recently said the shares screen as modestly undervalued on its GF Value measure, with a GF Score of 96 out of 100, reflecting strong profitability and growth. The same analysis noted heavy insider selling over the past year, even as a large group of so-called premium gurus continued to hold the stock, underlining the mixed signals that often accompany a company whose valuation and pipeline are both under close scrutiny.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
